MDP — Medexus Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- CA$87.10m
- CA$130.70m
- $113.05m
- 75
- 95
- 72
- 95
Annual income statement for Medexus Pharmaceuticals, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 55.5 | 79.7 | 76.7 | 108 | 113 |
| Cost of Revenue | |||||
| Gross Profit | 31.1 | 42 | 37.9 | 60 | 59.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 61.3 | 81 | 91.7 | 100 | 102 |
| Operating Profit | -5.79 | -1.38 | -15 | 7.61 | 10.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -5.54 | -31.5 | -3.82 | -5.04 | 0.106 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.7 | -28.3 | -2.88 | 1.22 | -0.214 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.7 | -28.3 | -2.88 | 1.22 | -0.214 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.7 | -28.3 | -2.88 | 1.22 | -0.214 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.117 | -1.77 | -0.06 | 0.087 | 0.048 |